BSE Live
Nov 28, 16:01Prev. Close
889.35
Open Price
889.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 28, 15:57Prev. Close
888.75
Open Price
890.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
878.40 (74)
| Cash Flow of Strides Pharma Science (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 2,905.14 | 69.62 | -64.76 | 21.51 | 111.64 | |
| Net CashFlow From Operating Activities | 421.48 | -35.76 | 241.74 | -282.69 | 282.76 | |
| Net Cash Used In Investing Activities | -137.59 | -61.27 | -182.58 | 18.78 | -275.64 | |
| Net Cash Used From Financing Activities | -370.32 | 107.62 | 10.82 | 250.73 | -48.64 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -86.42 | 10.60 | 69.98 | -13.18 | -41.52 | |
| Cash And Cash Equivalents Begin of Year | 92.75 | 82.11 | 12.12 | 25.30 | 66.82 | |
| Cash And Cash Equivalents End Of Year | 6.33 | 92.71 | 82.11 | 12.12 | 25.30 |
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
09.09.2025
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
29.07.2025
Strides Pharma Consolidated June 2025 Net Sales at Rs 1,119.74 crore, up 2.96% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016